Proteomics International Wins Canadian Patent for PromarkerEso Cancer Test
Proteomics International (ASX: PIQ) has secured a significant Canadian patent for its PromarkerEso diagnostic test, a first-in-class blood test for the early detection of esophageal adenocarcinoma (EAC). The patent strengthens (ASX: PIQ)’s intellectual property portfolio across North America and key global markets.
The Canadian Patent Office has granted Canadian Patent No. 2967869, titled ‘Glycoprotein Biomarkers For Esophageal Adenocarcinoma And Barrett’s Esophagus And Uses Thereof’, providing intellectual property protection until 17 November 2035. This regulatory milestone strengthens the Proteomics International PromarkerEso Canadian Patent position and establishes a foundation for commercial activity in North America.
The patent protects the proprietary blood test technology designed to detect esophageal adenocarcinoma at early stages, when treatment outcomes are significantly improved. PromarkerEso now holds patent protection across six major jurisdictions: Australia, Canada, China, Hong Kong, Europe, and the United States of America.
This multi-jurisdictional intellectual property framework enables three distinct revenue pathways: direct sales of the diagnostic test, strategic partnerships with healthcare providers and diagnostic laboratories, and licensing agreements. The Canadian patent positions the Company to pursue commercial opportunities in a market where chronic acid reflux (GERD) affects 20% of the population, creating substantial demand for accessible screening solutions.
Why Is Early Detection Important for Esophageal Adenocarcinoma Patients?
Esophageal cancer ranks seventh globally in cancer-related mortality and eleventh in overall prevalence. Esophageal adenocarcinoma, the predominant form of esophageal cancer, is commonly caused by chronic acid reflux (GERD) and is often asymptomatic in early stages, complicating diagnosis.
The survival statistics underscore the clinical urgency. The five-year survival rate is less than 20% with median survival time less than one year. Currently, up to 90% of EAC cases go undetected until late stage, despite existing surveillance methods.
The current gold-standard screening method, specialist endoscopy, presents significant barriers. The procedure costs approximately US$2,750 per patient in the United States, requires specialist resources, and can be uncomfortable for patients. Despite these investments, the invasive nature of endoscopy contributes to low screening uptake, allowing the vast majority of cases to progress undetected.
| Diagnostic Method | Invasiveness | Cost (US$) | Detection Rate | Patient Experience |
|---|---|---|---|---|
| Specialist Endoscopy (Current Standard) | Invasive procedure | $2,750 | Up to 90% of cases undetected | Uncomfortable, specialist required |
| PromarkerEso Blood Test | Non-invasive (blood sample) | Not disclosed | High accuracy (clinical studies) | Simple blood draw, accessible |
The clinical gap represents both a healthcare crisis and a commercial opportunity. Addressing the up to 90% undetected rate through a non-invasive, cost-effective screening tool could materially improve patient outcomes while reducing downstream healthcare costs associated with late-stage cancer treatment.
When big ASX news breaks, our subscribers know first
How Does PromarkerEso Blood Test Detect Esophageal Cancer Early?
PromarkerEso measures specific biomarkers (fingerprints) in blood to assess an individual’s risk of having esophageal adenocarcinoma. The technology combines biological markers with clinical factors, analysed through a proprietary algorithm to generate a clear risk classification.
The test incorporates four key serum glycoproteins: alpha-1-antitrypsin, alpha-1-antichymotrypsin, complement C9, and plasma kallikrein. These biomarkers are assessed alongside three clinical factors: age, sex, and body mass index (BMI). The proprietary algorithm processes this data to produce a ‘traffic light’ risk score, classifying individuals into low-risk, moderate-risk, or high-risk categories.
The testing process follows four steps: blood sample collection (a standard blood draw performed at a healthcare facility), biomarker analysis (laboratory measurement of the four glycoprotein levels), algorithm processing (proprietary software combines biomarker data with clinical factors), and risk classification (output generates a three-tier risk score). Patients identified as high-risk are recommended to consult a gastroenterologist for further evaluation, which may include endoscopy.
This stratified approach targets invasive procedures toward those most likely to benefit, improving resource allocation and patient experience. Clinical studies conducted in June and September 2025 demonstrated high accuracy in detecting EAC, including early-stage disease. The non-invasive nature of the test, combined with demonstrated clinical performance, positions PromarkerEso as a potential first-line screening tool for at-risk populations.
What Does the Canadian Patent Mean for PromarkerEso Commercialisation?
The Canadian patent establishes critical intellectual property protection that enables Proteomics International to pursue commercialisation strategies in North America. Patent protection until 17 November 2035 provides exclusivity during the critical market entry and scale-up phases.
The patent supports three distinct revenue pathways: direct sales (marketing and distributing the test through healthcare providers and diagnostic laboratories), strategic partnerships (collaborating with established diagnostic companies or healthcare networks), and licensing agreements (granting rights to third parties in exchange for licensing fees or royalties). The patent underpins the commercialisation pathway in North America, enabling direct sales, future partnerships, and licensing opportunities.
Canada serves as a strategic entry point to the broader North American market. The growing incidence of EAC, potentially related to western diet, increases market urgency and commercial viability. The Company has established a web portal at www.mytest.health to provide patient information and facilitate engagement with individuals concerned about chronic acid reflux or GERD.
The intellectual property framework de-risks commercial execution by protecting the proprietary algorithm and biomarker panel from competitor replication. This exclusivity is particularly valuable in diagnostic markets, where intellectual property strength influences partnership attractiveness and pricing power.
Building a Global IP Moat for Diagnostic Leadership
The expanded patent portfolio establishes a competitive moat across major global markets. PromarkerEso now holds intellectual property protection in six jurisdictions, covering key commercial territories and major diagnostic markets: Australia, Canada, China, Hong Kong, Europe, and the United States of America.
This multi-jurisdiction protection creates barriers to entry for potential competitors and supports international rollout strategies. The patent expiry date of 2035 provides over a decade of exclusivity, aligning with the typical commercialisation timeline for diagnostic technologies from regulatory approval through market penetration.
Proteomics International specialises in proteomics (the industrial-scale study of protein structure and function) and applies this expertise to develop innovative diagnostic tools. The Company’s mission centres on improving quality of life through precision diagnostics that enable the improved treatment of disease.
The first-in-class designation for PromarkerEso reflects both the novelty of the biomarker panel and the unmet need in esophageal adenocarcinoma screening. Patent protection across multiple territories de-risks the international expansion pathway and creates long-term value through market exclusivity during the critical growth phase.
The next major ASX story will hit our subscribers first
Investment Thesis: Positioning for North American Market Entry
The Proteomics International PromarkerEso Canadian Patent represents a de-risking milestone that transitions PromarkerEso from clinical development to commercial readiness in North America. The patent addresses three key investment considerations: revenue pathway clarity (intellectual property protection enables the Company to pursue direct sales, partnerships, or licensing without risk of IP infringement challenges), partnership optionality (exclusivity strengthens negotiating position with potential collaborators), and market access foundation (regulatory IP protection is a prerequisite for commercialisation discussions).
The addressable market presents substantial opportunity. With approximately 20% of the US population having GERD, and up to 90% of current EAC cases going undetected until late stage, PromarkerEso targets a significant diagnostic gap. The existing screening cost of US$2,750 per endoscopy creates economic headroom for a less invasive, more accessible blood test.
The patent grant follows clinical validation announcements in June and September 2025, demonstrating systematic progression toward commercialisation. The Company has secured regulatory IP protection ahead of market entry, reducing execution risk and positioning for near-term commercial traction in a large, underserved market.
Want more Biotech breakthroughs and analysis?
Stay informed with the free Big News Blasts, delivering breaking news and in-depth analysis from the biotech sector directly to your inbox. Join over 20,000 investors who rely on this no-cost service for timely updates on innovations like PromarkerEso and other market-moving developments. To start receiving these valuable insights, simply click the “Free Alerts” button at the top of the StockWire X site and sign up today.